ArticleWorld journal of gastrointestinal oncology2022

Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching.

Xavier Adhoute et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.